Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNASDAQ:FHTXNASDAQ:IMMXNASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$2.42+8.3%$1.46$1.05▼$4.13$241.00M1.54610,092 shs938,537 shsFHTXFoghorn Therapeutics$4.14$3.94$2.94▼$10.25$230.77M3.13140,908 shs70,400 shsIMMXImmix Biopharma$1.99-17.4%$1.82$1.26▼$2.71$55.48M0.27141,719 shs1.13 million shsPROKProKidney$0.71-3.6%$0.80$0.46▼$4.35$207.99M1.5676,802 shs637,917 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+28.80%+78.23%+47.71%-34.02%FHTXFoghorn Therapeutics0.00%-6.55%-7.38%-20.84%-33.44%IMMXImmix Biopharma0.00%-3.40%+13.71%+13.07%-7.44%PROKProKidney0.00%-11.90%-28.24%-52.63%-80.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics2.6932 of 5 stars4.52.00.00.02.10.80.6FHTXFoghorn Therapeutics2.4759 of 5 stars3.63.00.00.02.31.70.6IMMXImmix Biopharma1.9247 of 5 stars3.53.00.00.00.61.70.6PROKProKidney1.5943 of 5 stars3.30.00.00.00.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75220.91% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13192.87% UpsideIMMXImmix Biopharma 3.00Buy$7.00251.76% UpsidePROKProKidney 2.50Moderate Buy$5.00603.63% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, FHTX, PROK, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ADCTADC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/23/2025FHTXFoghorn TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025FHTXFoghorn TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$9.004/23/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.003/31/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.003/31/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025ADCTADC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$75.82M3.16N/AN/A($1.93) per share-1.25FHTXFoghorn Therapeutics$23.50M9.82N/AN/A($1.83) per share-2.26IMMXImmix BiopharmaN/AN/AN/AN/A$0.81 per shareN/APROKProKidney$306K679.71N/AN/A($4.84) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$240.05M-$1.45N/AN/AN/A-300.00%N/A-61.33%8/5/2025 (Estimated)FHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%N/AIMMXImmix Biopharma-$15.43M-$0.70N/AN/AN/AN/A-102.68%-80.89%8/11/2025 (Estimated)PROKProKidney-$35.47M-$0.60N/AN/AN/AN/AN/A-10.24%8/8/2025 (Estimated)Latest IMMX, FHTX, PROK, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million3/27/2025Q4 2024ADCTADC Therapeutics-$0.35-$0.29+$0.06-$0.29$19.01 million$19.00 million3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/A3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 million3/6/2025Q4 2024FHTXFoghorn Therapeutics-$0.43-$0.30+$0.13-$0.30$8.56 million$2.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.924.68FHTXFoghorn TherapeuticsN/A4.774.77IMMXImmix BiopharmaN/A3.473.47PROKProKidneyN/A17.0817.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%FHTXFoghorn Therapeutics61.55%IMMXImmix Biopharma11.26%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics4.10%FHTXFoghorn Therapeutics7.58%IMMXImmix Biopharma55.40%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million92.73 millionOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableIMMXImmix Biopharma927.88 million14.06 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableIMMX, FHTX, PROK, and ADCT HeadlinesRecent News About These CompaniesProKidney quarterly loss grows as it nears two key milestonesMay 15, 2025 | journalnow.comProKidney Reports First Quarter 2025 Financial Results and Business HighlightsMay 12, 2025 | globenewswire.comAnother Big Office Landlord Tests Sales ClimateMay 12, 2025 | bankerandtradesman.comPROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comProKidney (PROK) Expected to Announce Quarterly Earnings on FridayMay 4, 2025 | marketbeat.comWhy ProKidney Corp.’s (PROK) Stock Is Down 6.09%April 28, 2025 | aaii.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of StockApril 25, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 7.90%April 17, 2025 | aaii.comProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in StockApril 17, 2025 | insidertrades.comGreensboro’s Once Great Win Is Now A ProKidney FailureApril 16, 2025 | rhinotimes.comControl Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 15, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 9.90%April 10, 2025 | aaii.comWhy ProKidney Corp.’s (PROK) Stock Is Down 14.87%April 8, 2025 | aaii.comProKidney Corp.March 30, 2025 | wsj.comHere's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn SituationMarch 27, 2025 | finance.yahoo.comDown -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)March 21, 2025 | zacks.comProKidney reports larger loss in 2024 as production resumesMarch 18, 2025 | journalnow.comProKidney reports FY24 EPS (62c), consensus (59c)March 17, 2025 | markets.businessinsider.comProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney DiseaseMarch 17, 2025 | quiverquant.comProKidney Reports Full Year 2024 Financial Results and Business HighlightsMarch 17, 2025 | globenewswire.comWhy ProKidney Corp.’s (PROK) Stock Is Down 10.96%February 26, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, FHTX, PROK, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$2.42 +0.19 (+8.30%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.38 -0.04 (-1.45%) As of 05/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Foghorn Therapeutics NASDAQ:FHTX$4.14 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.14 +0.00 (+0.12%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Immix Biopharma NASDAQ:IMMX$1.99 -0.42 (-17.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.75%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.ProKidney NASDAQ:PROK$0.71 -0.03 (-3.57%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.72 +0.01 (+1.18%) As of 05/23/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
